CRAVES FRED B 4
4 · MADRIGAL PHARMACEUTICALS, INC. · Filed Dec 5, 2024
Insider Transaction Report
Form 4
CRAVES FRED B
Director
Transactions
- Sale
Common Stock
2024-12-03$315.21/sh−3,080$970,852→ 11,520 total(indirect: See Footnotes) - Sale
Common Stock
2024-12-03$315.90/sh−520$164,270→ 11,000 total(indirect: See Footnotes)
Holdings
- 11,210(indirect: See Footnote)
Common Stock
- 360,076
Common Stock
- 1,261(indirect: See Footnotes)
Common Stock
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.00 to $315.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
- [F2]Represents shares held indirectly by Dr. Craves through the Craves Family Foundation.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.84 to $316.16, inclusive.
- [F4]Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust.
- [F5]These securities are held by Bay City Capital LLC ("BCC"). Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.